Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone Administered Intravenously to Patients With Colorectal Adenocarcinoma Previously Untreated for Metastatic Disease

NCT00890305 is registered in ClinicalTrials.gov with Medivation, Inc. as lead sponsor.

NCT NCT00890305
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00890305 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone Administered Intravenously to Patients With Colorectal Adenocarcinoma Previously Untreated for Metastatic Disease
Lead sponsor
Medivation, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2009
Completion date
March 31, 2013
Enrollment
171 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer